Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
TACC3
REST API REST API
Homo sapiens
TACC3 is differentially expressed in 262 experiments: 122 organism parts: bone marrow, thymus, ... (120 more);, 201 disease states: normal, colon carcinoma, ... (199 more);, 92 cell types 304 cell lines 36 compound treatments and 68 other conditions.
Synonyms ERIC1
Orthologs TACC3 (Gallus gallus)   A6QL93_BOVIN (Bos taurus)   Tacc3 (Mus musculus)   Tacc3 (Rattus norvegicus)   tacc3 (Danio rerio)   ENSCING00000013819 (Ciona intestinalis)   tacc (Drosophila melanogaster)   tacc3 (Xenopus laevis)   TACC3 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytoplasm, cell proliferation, neurogenesis, response to stress, protein domain specific binding, cytoplasmic sequestering of transcription factor, hemopoiesis, centrosome, regulation of cell cycle, microtubule cytoskeleton organization, cerebral cortex development, regulation of microtubule-based process, interkinetic nuclear migration, astral microtubule organization
InterPro Term TACC
UniProt Accession Q9Y6A5, Q8IX09, C9JA91, C9JWI7, E7EMT0, F8WC55
Gene-Disease Assocation BLADDER CANCER
Search EB-eye ENSG00000013810
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-GEOD-1577, E-MTAB-24, E-MTAB-25, ... (22 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, ... (36 experiments)

Factor Value U/D Experiments
BT474
3
E-MEXP-440, E-MTAB-62, E-MTAB-37
MCF-7
3
E-GEOD-5823, E-GEOD-20081, E-GEOD-19639
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
MOLT4
2
E-MTAB-37, E-MTAB-62
PC3
2
E-GEOD-5258, E-MEXP-2034
HL-60
1
2
E-GEOD-24147, E-GEOD-5258, E-MTAB-37
298 more value(s).


Cell type

studied in E-MEXP-1242, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-MEXP-66, ... (44 experiments)

Factor Value U/D Experiments
fibroblast
2
E-GEOD-3920, E-GEOD-3204
hematopoietic stem cell
2
E-MEXP-872, E-MEXP-1403
mesendoderm/endoderm progenitor cell
1
E-MEXP-930
kidney cell
1
E-MEXP-1216
platelet
1
E-GEOD-2006
spheroid recovery
1
E-GEOD-4219
86 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-MEXP-1121, E-TABM-15, ... (55 experiments)

Factor Value U/D Experiments
cervical carcinoma
3
E-MTAB-62, E-MTAB-37, E-MEXP-1331
glioblastoma
3
E-GEOD-4290, E-GEOD-6014, E-GEOD-4412
colon carcinoma
1
3
E-MTAB-62, E-MTAB-57, E-GEOD-3726, E-MTAB-37
prostate carcinoma
2
E-MTAB-62, E-MEXP-2034
acute lymphoblastic leukemia
2
E-MTAB-62, E-MTAB-37
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-995
195 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-6907, E-GEOD-1417, E-TABM-782, E-GEOD-3720, ... (24 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-MEXP-1958, E-GEOD-3720
control
1
E-GEOD-4006
ponasterone A
1
E-GEOD-3113
bis [(+)-tartrato] diantimonate (III) dipotassium trihydrate
1
E-GEOD-6907
control - keratinocyte growth factor
1
E-GEOD-7216
neocarzinostatin
1
E-GEOD-1676
30 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-2034, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-20033, E-MEXP-2359, E-MTAB-62

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-GEOD-19665

Environmental stress
studied in E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-4025, E-GEOD-17385, E-GEOD-20847, E-MTAB-108, ... (7 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-17476, E-MEXP-421, E-TABM-321, E-GEOD-18736, ... (8 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-GEOD-20504, E-GEOD-19018, ... (10 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-2748

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-1290, E-TABM-666, E-GEOD-19330, ... (24 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561 ... (5 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-TABM-321

Ki67 ihc
studied in E-GEOD-21653

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-19703, E-GEOD-21750, E-GEOD-1657, E-GEOD-4600, ... (6 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

Replicate
studied in E-GEOD-10797

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-GEOD-1676, E-MEXP-1315, E-MEXP-2759 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-16363

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276, E-GEOD-2748

Tissue
studied in E-GEOD-30573

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-21909, E-GEOD-19246, E-GEOD-15799, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-3494, E-GEOD-6532, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.478 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM